464
Participants
Start Date
April 17, 2012
Primary Completion Date
January 22, 2014
Study Completion Date
January 22, 2014
Lisdexamfetamine dimesylate
Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
Methylphenidate Hydrochloride
Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
Placebo
Daily oral dosing in the AM for 8 weeks
Mount Sinai School of Medicine, New York
NeuroScience, Inc., Herndon
Neuroscientific InSights, Rockville
Marc Hertzman MD, PC, Rockville
University of Virginia Child and Family Psychiatry Clinical, Charlottesville
Duke Child and Family Study Center, Durham
Carolina Clinical Trials, Inc., Charleston
Coastal Carolina Research Center, Mt. Pleasant
Atlanta Institute of Medicine and Research, Atlanta
Clinical Neuroscience Solutions, Inc., Jacksonville
Sarkis Clinical Trials, Gainesville
Florida Clinical Research Center, LLC, Maitland
Clinical Neuroscience Solutions, Inc., Orlando
Compass Research, LLC, Orlando
Amedica Research Institute, Hialeah
Scientific Clinical Research, Inc., Miami
Fidelity Clinical Research, Inc., Lauderhill
Janus Center for Psychiatric Research, West Palm Beach
Stedman Clinical Trials, Tampa
Florida Clinical Research Center, LLC, Bradenton
Research Strategies of Memphis, LLC, Memphis
Precise Research Centers, Flowood
University of Kentucky, Lexington
Four Rivers Clinical Research, Paducah
The Ohio State University Nisonger Center, Columbus
North Coast Clinical Trials, Beachwood
Cleveland Clinic, Cleveland
Family Practice of Wadsworth, Inc., Wadsworth
Professional Psychiatric Services, Mason
University of Cincinnati Dept. of Psychiatry & Behavioral, Cincinnati
Midwest Clinical Research Center, Dayton
Behavioral Medical Center - Troy, Troy
Rochester Center for Behavioral Medicine, Rochester Hills
Clinical Neurophysiology Services, PC, Sterling Heights
Innovis Health, LLC, Fargo
Capstone Clinical Research, Libertyville
Neuroscience Research Institute, Inc, Oak Park
Advocate Hope Children's Hospital, Oak Lawn
American Medical Research, Inc, Oak Brook
AMR Baber Research Group, Inc., Naperville
AMR Conventions Research, Naperville
St Charles Psychiatric Associates, Saint Charles
Comprehensive Psychiatric Associates, Gladstone
Psychiatric Associates, Overland Park
University of Nebraska Medical Center, Omaha
Premier Psychiatric Research Institute, Lincoln
Clinical Study Centers, LLC, Little Rock
Claghorn-Lesem Reseach Clinic, Ltd., Houston
Texas Center for Drug Development, Inc., Houston
Red Oak Psychiatry Associates, PA, Houston
Wharton Research Center, Inc., Wharton
R/D Clinical Research, Inc., Lake Jackson
Clinical Trials of Texas, Inc., San Antonio
University of Texas HSC at San Antonio Dept. of Psychiatry, San Antonio
FutureSearch Trials, Austin
Westex Clinical Investigations, Lubbock
MCB Clinical Research Centers, LLC, Colorado Springs
Psychiatric & Behavioral Solutions, Salt Lake City
Melmed Center, Scottsdale
Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas
Peninsula Research Associates, Inc., Rolling Hills Estates
Synergy Clinical Research Center, National City
PCSD - Feighner Research, San Diego
Elite Clinical Trials, Wildomar
Neuropsychiatric Research Center of Orange County, Santa Ana
Pacific Clinical Research Medical Group, Orange
SDS Clinical Trials, Inc., Orange
University of California, San Francisco, San Francisco
Cyn3rgy Research, Gresham
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.), Portland
Summit Research Network (Oregon) Inc., Portland
Oregon Center for Clinical Investigations, Inc., Salem
Northwest Clinical Research Center, Bellevue
Eastside Therapeutic Resource, Kirkland
Summit Research Network (Seattle), LLC, Seattle
Rockwood Clinic, P.S., Spokane
Center for Emotional Fitness, Cherry Hill
CRCNJ - Clinical Research Center of New Jersey, Gibbsboro
Neurcognitive Institute, Mount Arlington
Lead Sponsor
Shire
INDUSTRY